We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Toxicology

Annals of Medicine

In the Toxicology section of Annals of Medicine we consider for publication the latest advances in:

•Drug Metabolism

•Pharmacokinetics

•Pre-clinical Toxicology

•Safety Assessment

•Toxicology

Q1 Rank

Two-Year Impact Factor 3.243

Five-Year Impact Factor 3.840

-Journal Citation Reports®

 

MEDLINE® Indexed

 

CiteScore 5.70

- Scopus®

Meet the Section Editor

Rakesh Dixit, CEO & President, Bionavigen, LLC

Rakesh Dixit is President & CEO at BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in drug hunting, advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. He conducted extensive graduate and post-graduate training in pharmacology, toxicology and biochemistry at both Indian and US institutions (Case Wester Reserve University, Medical College of Ohio and the University of Nebraska) and is a Diplomate and Board Certified in Toxicology from the American Board of Toxicology Inc since 1992. Dixit is an accomplished executive, inventor and scientist with over 30 years of success, working with top biotechnology and pharmaceutical companies. In 2015, Dixit was selected by PharmaVoice as one of the 100 Most Inspiring People in the Pharmaceutical Industry. Dixit was a key contributor to the development and approval of ten blockbuster pharmaceuticals to the market. Currently Editor-in-Chief of Toxicology Mechanisms and Methods, and Associate Editor of Toxicology Applied Pharmacology and the Journal of Toxicology and Environmental Health—Dixit has published more than 80 peer-reviewed papers and delivered over 130 invited lectures, presentations and workshops.

Why is Annals of Medicine the Best Publication for Your Research?

Fully open access, general medical journal publishing articles under a CC BY license, allowing maximum sharing and reuse of articles to our international readership;

Publishing all scientifically valid research, including reporting of negative and null data, from translational to clinical research in all disciplines and therapy areas;

Led by an international editorial team of subject experts who ensure a constructive and rigorous peer review process;

Your research is promoted via a tailored, multi-channel approach to maximize visibility, readership and impact.